| 1. | Guyatt G, Baumann M, Pauker S, et al. Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force. Chest, 2006, 129(1): 182-187. | 
				                                                        
				                                                            
				                                                                | 2. | Eddy DM. Comparing benefits and harms: the balance sheet. JAMA, 1990, 263(18): 2493, 2498, 2501. | 
				                                                        
				                                                            
				                                                                | 3. | Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Lancet, 2002, 359(9321): 1877-1890. | 
				                                                        
				                                                            
				                                                                | 4. | Simon J, Gray A, Duley L. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the magpie trial. Br J Obstet Gynaecol, 2006, 113(2): 144-151. | 
				                                                        
				                                                            
				                                                                | 5. | Montori VM, Jaeschke R, Schünemann HJ, et al. Users’ guide to detecting misleading claims in clinical research reports. BMJ, 2004, 329(7474): 1093-1096. | 
				                                                        
				                                                            
				                                                                | 6. | Luce B, Manning W, Siegel J. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996: 176-213. | 
				                                                        
				                                                            
				                                                                | 7. | Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA, 1999, 282(15): 1453-1457. | 
				                                                        
				                                                            
				                                                                | 8. | Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ, 1997, 16(1): 1-31. | 
				                                                        
				                                                            
				                                                                | 9. | Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med, 1998, 13(10): 716-717. | 
				                                                        
				                                                            
				                                                                | 10. | Gold M, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996. | 
				                                                        
				                                                            
				                                                                | 11. | O’Brien B, Drummond M, Richardson WS, et al. Economic analysis. In: Guyatt G, Rennie D, eds. Users’ guides to the medical literature. Chicago: AMA Press, 2002, 621-644. |